Standard Treatment Meglumine antimoniate
Phase 2Small molecule
Standard Treatment Meglumine antimoniate is one of 16 small molecule programs targeting Leishmaniasis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Leishmaniasis
#DrugCompanyPhaseTrials
1Ornidyl
UUSWM, LLC (dba US WorldMeds)
Approved
Garamycin
SSchering-Plough
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Pentam
FFresenius Kabi Oncology Ltd.
Approved
Vfend
PPrism Pharmaceuticals
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Trental
VValidus Pharmaceuticals
Phase 3
Liposomal Lurtotecan
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Leishmaniasis1 trial
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
Completed·—·Phase 2·NCT01377974·40 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBrasilia University Hospital